Biopharmaceutical News and Research

RSS
CN Bio raises $21 million USD in first close of Series B investment round

CN Bio raises $21 million USD in first close of Series B investment round

MD Anderson and CureVac collaborate on mRNA-based cancer vaccines

MD Anderson and CureVac collaborate on mRNA-based cancer vaccines

Hip fracture survival rates in seniors worse than many cancers, study shows

Hip fracture survival rates in seniors worse than many cancers, study shows

New technique reveals insights into gut cell dynamics during inflammation

New technique reveals insights into gut cell dynamics during inflammation

Ubiquigent and Debiopharm enter agreement to support USP1 inhibitor programme for Debio 0432

Ubiquigent and Debiopharm enter agreement to support USP1 inhibitor programme for Debio 0432

ArgusEye introduces AugaOne to accelerate downstream bioprocess development

ArgusEye introduces AugaOne to accelerate downstream bioprocess development

Precision unveiled: Exploring the cutting-edge of analytical weighing with Cubis® II ultra-high resolution balances

Precision unveiled: Exploring the cutting-edge of analytical weighing with Cubis® II ultra-high resolution balances

Biden is right. The US generally pays double that of other countries for Rx drugs.

Biden is right. The US generally pays double that of other countries for Rx drugs.

BioCina and NovaCina forge strategic alliance to offer biologics developers integrated drug substance and drug product solutions

BioCina and NovaCina forge strategic alliance to offer biologics developers integrated drug substance and drug product solutions

MD Anderson acquires cell therapy safety technology from Bellicum Pharmaceuticals

MD Anderson acquires cell therapy safety technology from Bellicum Pharmaceuticals

Novel synthetic antibiotic effective against drug-resistant bacteria

Novel synthetic antibiotic effective against drug-resistant bacteria

CARB-X awards $1.8 million to Visby Medical to develop a portable rapid PCR test for gonorrhea

CARB-X awards $1.8 million to Visby Medical to develop a portable rapid PCR test for gonorrhea

Enterprise Therapeutics closes £26 million ($33.1 million) Series B follow-on financing

Enterprise Therapeutics closes £26 million ($33.1 million) Series B follow-on financing

Balancing efficacy and safety: The challenges of mRNA drugs and vaccines in modern medicine

Balancing efficacy and safety: The challenges of mRNA drugs and vaccines in modern medicine

New blood test technique raises hopes for more sensitive and earlier cancer diagnosis

New blood test technique raises hopes for more sensitive and earlier cancer diagnosis

£30M clinical study will enhance the understanding of NASH cirrhosis

£30M clinical study will enhance the understanding of NASH cirrhosis

Scripps Research commemorates 100 years of innovation in science and medicine

Scripps Research commemorates 100 years of innovation in science and medicine

Bridging ideas to IND: Nona Biosciences' year of impact in biotechnology

Bridging ideas to IND: Nona Biosciences' year of impact in biotechnology

UMass Amherst researchers develop novel strategy to outsmart antibiotic-resistant ‘superbugs’

UMass Amherst researchers develop novel strategy to outsmart antibiotic-resistant ‘superbugs’

UVA atlas unveils cellular blueprint of atherosclerosis

UVA atlas unveils cellular blueprint of atherosclerosis

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.